8-K: Cognition Therapeutics Reports Year-End 2023 Financial Results and Provides Business Update

Cognition Therapeutics announced its 2023 financial results, highlighted clinical trial progress, and secured additional funding to extend its cash runway through May 2025.

Summary

• Cognition Therapeutics reported its financial results for the year ended December 31, 2023, including a net loss of $25.8 million, or $(0.86) per share.
• The company's research and development expenses increased to $37.2 million in 2023 from $30.3 million in 2022, primarily due to higher costs associated with Phase 2 trial activities.
• General and administrative expenses were $13.5 million in 2023, compared to $13.2 million in 2022.
• As of December 31, 2023, the company had $29.9 million in cash and cash equivalents, and $67.5 million in remaining grant funds from the NIA.
• In March 2024, Cognition raised approximately $10.4 million through a public offering of 6,571,428 shares at $1.75 per share.
• The company expects its current cash reserves to fund operations through May 2025.
• Topline results from the Phase 2 SHINE study in mild-to-moderate Alzheimer's disease are expected mid-2024, and topline results from the Phase 2 SHIMMER study in mild-to-moderate DLB are expected in the second half of 2024.

Sentiment

Score: 7

Explanation: The document presents a mix of positive and negative aspects. The clinical progress and extended cash runway are positive, but the increased net loss and R&D expenses are concerning. Overall, the sentiment is cautiously optimistic.

Positives

• The company successfully completed enrollment in the Phase 2 SHINE study.
• The company has secured funding to extend its cash runway through May 2025.
• The company is advancing multiple clinical programs in Alzheimer's disease, DLB, and dry AMD.
• The company has published research and presented at scientific conferences, advancing the understanding of its science.
• The FDA approval of disease-modifying biologics for Alzheimer's has re-invigorated research and investment in the sector.

Negatives

• The company reported a net loss of $25.8 million for 2023, an increase from the $21.4 million loss in 2022.
• The company's cash and cash equivalents decreased from $41.6 million at the end of 2022 to $29.9 million at the end of 2023.
• Research and development expenses increased significantly in 2023.

Risks

• The company's future success depends on the outcome of its clinical trials, which are subject to risks and uncertainties.
• The company may face competition from other companies developing treatments for neurodegenerative disorders.
• The company's ability to secure new grant funding and manage growth is critical to its success.
• The company's financial results are subject to various economic, business, and competitive factors.
• The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.

Future Outlook

The company anticipates topline results from the SHINE and SHIMMER studies in 2024 and expects to use these results to inform the next phase of its evolution. The company also expects its current cash reserves to fund operations through May 2025.

Management Comments

• We achieved a number of critical clinical objectives in 2023, said Lisa Ricciardi, Cognitions president and CEO.
• We are pleased with the progress being made with our clinical trial partners to advance our Phase 2 studies.
• The FDA approval in 2023 of the first disease-modifying biologics for Alzheimers disease was a much-needed advance for the development of new drugs to treat Alzheimers and other neurological conditions, said Ms. Ricciardi.

Industry Context

The FDA approval of disease-modifying biologics for Alzheimer's disease has re-invigorated research and investment in the sector, which is a positive development for Cognition Therapeutics and its pipeline. The company is also focusing on other neurodegenerative disorders, such as DLB and dry AMD, which are areas of unmet medical need.

Comparison to Industry Standards

• Cognition's focus on sigma-2 receptor modulation is a unique approach compared to other companies developing treatments for Alzheimer's disease, such as Biogen and Eisai with their anti-amyloid antibodies.
• The company's clinical trial timelines are consistent with other biotech companies in the space, with topline results expected in the near term.
• The company's cash runway through May 2025 is a positive sign, but it will need to secure additional funding to continue its clinical programs beyond that date.
• The company's net loss is typical for a clinical-stage biotech company, but it will need to demonstrate clinical efficacy to attract further investment.

Management Changes

Stakeholder Impact

• Shareholders will be interested in the clinical trial results and the company's financial performance.
• Employees will be impacted by the company's growth and financial stability.
• Patients with neurodegenerative disorders will be impacted by the potential development of new treatments.
• Investors will be interested in the company's ability to secure additional funding and achieve clinical milestones.

Next Steps

• The company will report topline results from the Phase 2 SHINE study in mid-2024.
• The company will report topline results from the Phase 2 SHIMMER study in the second half of 2024.
• The company will continue to advance its clinical programs in early Alzheimer's disease and dry AMD.
• The company will analyze samples from study participants to identify candidate biomarkers of CT1812 activity.

Key Dates

Keywords

Alzheimer's disease, dementia with Lewy bodies, dry age-related macular degeneration, CT1812, clinical trials, neurodegenerative disorders, biopharmaceutical, sigma-2 receptor, financial results, capital raise